Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 515
- Registration Number
- NCT04590586
- Locations
- 🇺🇸
The University of Iowa, Iowa City, Iowa, United States
🇺🇸Sharp Chula Vista Medical Center, Chula Vista, California, United States
🇷🇺SPb SBIH "Alexandrovskaya City Hospital", Saint Petersburg, Russian Federation
Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 36
- Registration Number
- NCT04586660
- Locations
- 🇨🇳
Beijing Jishuitan Hospital, Beijing, Beijing, China
🇨🇳Peking University Peoples Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease
- Conditions
- Chronic (Inactive) Thyroid Eye DiseaseThyroid Eye Disease
- Interventions
- Biological: TEPEZZADrug: Placebo
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Amgen
- Target Recruit Count
- 62
- Registration Number
- NCT04583735
- Locations
- 🇺🇸
MACRO Trials, Los Angeles, California, United States
🇺🇸Las Vegas Endocrinology, Las Vegas, Nevada, United States
🇺🇸Bascom Palmer Eye Institute / Univ of Miami, Miami, Florida, United States
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
- Conditions
- IgG4 Related Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 135
- Registration Number
- NCT04540497
- Locations
- 🇬🇧
Viela Bio Investigative Site, Oxford, United Kingdom
🇪🇸Viela Bio Investigative Site 2, Barcelona, Spain
🇨🇳Viela Bio Investigative Site 1, Beijing, China
Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 17
- Registration Number
- NCT04524455
- Locations
- 🇫🇷
Centre Hospitalier Lyon Sud, Pierre Benite, France
🇪🇸Hospital Universitari Germans Trias i Pujol, Badalona, Cataluña, Spain
🇩🇪Universitätsklinikum Schleswig-Holstein, Kiel, Germany
A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients
- Conditions
- B Cell Precursor Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 125
- Registration Number
- NCT04521231
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Fred Hutchinson Cancer Center, Seattle, Washington, United States
Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
- Conditions
- B-precursor Acute Lymphoblastic Leukemia
- Interventions
- Device: Current Wearable Heatlth Monitoring System (CWHMS)
- First Posted Date
- 2020-08-10
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 10
- Registration Number
- NCT04506086
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸University of California Irvine, Orange, California, United States
Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1
- Registration Number
- NCT04478695
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 110
- Registration Number
- NCT04478708
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸Orange County Research Center, Tustin, California, United States
🇺🇸Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- Biological: TEPEZZAOther: Placebo
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 3
- Registration Number
- NCT04478994
- Locations
- 🇺🇸
UCLA Division of Rheumatology, Los Angeles, California, United States
🇺🇸Pacific Arthritis Care Center, Los Angeles, California, United States
🇺🇸The Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States